Bipolar Disorder - Canada Drug Forecast and Market Analysis to 2024

Summary

Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka's Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period.

The author estimates the value of the Canadian bipolar disorder market to have been approximately $167.8m in 2014. Canada's market size is limited by the country's low population. Drug sales in this country are expected to stay largely constant over the forecast period, as represented by the flat CAGR. Sales are then expected to decline between 2017 and 2023 due to the generic erosion of various brands including Otsuka's Abilify, Pfizer's Zeldox, Allergan's Saphris, and Janssen's Risperdal Consta.

Scope

- Overview of Bipolar Disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Canada including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Canada from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting Canada Bipolar Disorder market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Bipolar Disorder.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in Canada.

Contents:

1.1 List of Tables
1.2 List of Figures
2 Introduction
   2.1 Catalyst
   2.2 Related Reports
   2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification
3.3 Symptoms
3.4 Prognosis
4 Disease Management
4.1 Diagnosis Overview
4.1.1 Clinical Evaluation
4.1.2 Screening Tools
4.2 Treatment Overview
4.2.1 Treatment Initiation and Maintenance Therapy
4.2.2 Manic or Mixed Episodes
4.2.3 Acute Agitation
4.2.4 Hypomanic Episodes
4.2.5 Major Depressive Episodes
4.2.6 Rapid Cycling
4.2.7 Cyclothymia
4.2.8 Other Treatment Factors
4.3 Treatment Guidelines and Leading Prescribed Drugs
4.4 Canada
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles - Major Brands
5.2.1 Lithium
5.2.2 Anticonvulsants
5.2.3 Typical Antipsychotics
5.2.4 Atypical Antipsychotics
5.2.5 Antidepressants
5.3 Other Therapeutic Classes
6 Unmet Need and Opportunity
6.1 Overview

6.2 Effective Treatment Options for Bipolar Depression
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity

6.3 Antipsychotics with a Low Risk of EPS and Metabolic Changes
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity

6.4 Mood Stabilizers with Improved Safety Profiles
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity

6.5 Education for Physicians in Order to Improve Diagnosis Rates
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity

6.6 Novel Drugs Developed Specifically for Bipolar Disorder
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity

7 Pipeline Assessment
7.1 Overview
7.1.1 Clinical Trials by Class of Therapy

7.2 Promising Drugs in Clinical Development
7.2.1 Abilify Maintena
7.2.2 ITI-007

7.3 Off-label Pipeline and Recently Approved Therapies

7.4 Promising Drugs in Early-Stage Development

7.5 Other Drugs in Development

8 Market Outlook
8.1 Canada
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Bipolar Disorder Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Launch and Patent Expiry Dates
9.4.4 General Pricing Assumptions
9.4.5 Individual Drug Assumptions
9.4.6 Generic Erosion
9.5 Primary Research - KOLs Interviewed for this Report
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Analyst
9.7.2 Therapy Area Director
9.7.3 Epidemiologist
9.7.4 Global Director of Therapy Research and Analysis
9.8
9.9 Disclaimer
1.1 List of Tables
Table 1: Classification and Criteria of Bipolar Disorder According to DSM-V and ICD-10-CM
Table 2: DSM-V Bipolar Disorder Specifiers
Table 3: Symptoms of Manic, Hypomanic, and Major Depressive Episodes in Bipolar Disorder
Table 4: Screening Tools Used for Bipolar Disorder
Table 5: Treatment Guidelines for Bipolar Disorder
Table 6: Most Prescribed Drugs for Bipolar Disorder by Episode Type in the Global Markets, 2014
Table 7: Country Profile - Canada
Table 40: Product Profile - Geodon
Table 41: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Geodon
Table 42: Geodon SWOT Analysis, 2015
Table 43: Global Sales Forecasts ($m) for Geodon, 2014-2024
Table 44: Product Profile - Latuda
Table 45: Efficacy Results for Latuda in Bipolar Depression Trials
Table 46: Adverse Events at ≥2% Incidence in Bipolar Depression Trials of Latuda
Table 47: Latuda SWOT Analysis, 2015
Table 48: Global Sales Forecasts ($m) for Latuda, 2014-2024
Table 49: Product Profile - Risperdal
Table 50: Efficacy Results for Risperdal in Trial of Manic and Mixed Bipolar Episodes
Table 51: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Risperdal
Table 52: Adverse Events at ≥2% Incidence in Bipolar Maintenance Trials of Risperdal Consta
Table 53: Risperdal SWOT Analysis, 2015
Table 54: Global Sales Forecasts ($m) for Risperdal, 2014-2024
Table 55: Global Sales Forecasts ($m) for Risperdal Consta, 2014-2024
Table 56: Product Profile - Saphris
Table 57: Efficacy Results for Saphris in Bipolar Mania Studies
Table 58: Adverse Events at ≥2% Incidence in Bipolar I Disorder Trials of Saphris
Table 59: Saphris SWOT Analysis, 2015
Table 60: Global Sales Forecasts ($m) for Saphris, 2014-2024
Table 61: Product Profile - Seroquel
Table 62: Efficacy Results for Seroquel in Bipolar Mania Studies
Table 63: Efficacy Results for Seroquel in Bipolar Depression Trials
Table 64: Efficacy Results for Seroquel XR in Bipolar Disorder Trials
Table 65: Adverse Events at ≥2% Incidence in Bipolar Disorder Trials of Seroquel
Table 66: Adverse Events at ≥2% Incidence in Bipolar Disorder Trials of Seroquel XR
Table 67: Seroquel SWOT Analysis, 2015
Table 68: Global Sales Forecasts ($m) for Seroquel, 2014-2024
Table 69: Global Sales Forecasts ($m) for Seroquel XR, 2014-2024
Table 70: Product Profile - Symbyax
Table 71: Efficacy Results for Symbyax in Bipolar Depression Trials
Table 72: Adverse Events at =2% Incidence in Bipolar Depression and Treatment-Resistant Depression Trials of Symbyax
Table 73: Symbyax SWOT Analysis, 2015
Table 74: Global Sales Forecasts ($m) for Symbyax, 2014-2024
Table 75: Product Profile - Vraylar
Table 76: Vraylar SWOT Analysis, 2015
Table 77: Global Sales Forecast ($) for Vraylar, 2014-2024
Table 78: Product Profile - Zyprexa
Table 79: Adverse Events at =2% Incidence in Bipolar Mania Trials of Zyprexa
Table 80: Adverse Events at =2% Incidence in Trials of Zyprexa IntraMuscular in Agitation Associated with Schizophrenia or Bipolar I Mania
Table 81: Zyprexa SWOT Analysis, 2015
Table 82: Global Sales Forecasts ($m) for Zyprexa, 2014-2024
Table 83: Product Information for the Most Commonly Prescribed “Other Antipsychotics”
Table 84: International Society for Bipolar Disorders Clinical Recommendations for Antidepressant Use in Bipolar Disorder
Table 85: Antidepressants SWOT Analysis, 2015
Table 86: Global Sales Forecasts ($m) for the Antidepressants, 2014-2024
Table 87: Summary of Minor Therapeutic Classes, 2015
Table 88: Unmet Need and Opportunity in Bipolar Disorder
Table 89: Product Profile - Abilify Maintena
Table 90: Adverse Events at =2% Incidence in a Schizophrenia Trial of Abilify Maintena
Table 91: Abilify Maintena SWOT Analysis, 2015
Table 92: Global Sales Forecast ($) for Abilify Maintena, 2014-2024
Table 93: Product Profile - ITI-007
Table 94: Efficacy Results for ITI-007 in a Phase II Schizophrenia Trial
Table 95: Key Safety Data From a Phase II in a Schizophrenia Trial of ITI-007
Table 96: ITI-007 SWOT Analysis, 2015
Table 97: Potential Off-label Bipolar Disorder Late-Stage Pipeline Drugs
Table 98: Drugs in Development, 2015
Table 99: Sales Forecasts ($m) for Bipolar Disorder in Canada, 2014-2024
Table 100: Key Events Impacting Sales for Bipolar Disorder in Canada, 2014-2024
Table 101: Bipolar Disorder Market in Canada - Drivers and Barriers, 2014-2024

Table 102: Key Launch Dates

Table 103: Key Patent Expiries

Table 104: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

1.2 List of Figures

Figure 1: The Etiology and Pathophysiology of Bipolar Disorders

Figure 2: The Effects of Lithium on Neurotransmission

Figure 3: The Effects of Lithium on Second Messenger Pathways

Figure 4: Bipolar Disorder Therapeutics - Class of Therapy, 2016

Figure 5: Bipolar Disorder - Phase II-III Pipeline, 2015

Figure 6: Clinical and Commercial Positioning of Abilify Maintena

Figure 7: Clinical and Commercial Positioning of ITI-007

Figure 8: Sales for Bipolar Disorder in Canada by Drug Class, 2014-2024

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3756909/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Bipolar Disorder - Canada Drug Forecast and Market Analysis to 2024
Web Address: http://www.researchandmarkets.com/reports/3756909/
Office Code: SCH3FXNI

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 4995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 9990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 14985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________  Last Name: ___________________________
Email Address: * _______________________
Job Title: ____________________________
Organisation: _________________________
Address: ______________________________
City: _________________________________
Postal / Zip Code: _____________________
Country: ______________________________
Phone Number: _________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World